Phoxillum Solution 

Phoxillum Solution Overview

Maintaining precise fluid, electrolyte, and acid-base balance is a fundamental clinical challenge when treating critically ill patients with acute kidney injury. The specialized multi-component solution containing Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, and Sodium Phosphate widely known under the brand name Phoxillum is an advanced sterile replacement and hemodialysis solution. Utilized extensively in intensive care units, critical care medicine, and nephrology, this balanced crystalloid solution is formulated specifically for continuous renal replacement therapy (CRRT).

What Is Phoxillum Solution and How Does It Work?

Phoxillum is a sterile, non-pyrogenic replacement and dialysate fluid engineered to match extracellular fluid composition during continuous kidney replacement procedures. In acute renal failure, failing kidneys cannot clear nitrogenous waste, regulate blood volume, or balance electrolytes. During CRRT, blood passes continuously through a semipermeable membrane. Phoxillum acts as a substitute for normal plasma ultrafiltrate, removing toxic metabolic wastes while supplying necessary electrolytes to prevent depletion.

Is Phoxillum Solution FDA Approved?

Yes, Phoxillum solution is fully FDA approved. It received its initial regulatory approval in (January 2015) and serves as a vital therapeutic tool for intensive care units conducting continuous renal replacement therapy.

What Is Phoxillum Solution Used For?

• Continuous Renal Replacement Therapy (CRRT): Indicated for use as a replacement solution or dialysate in continuous hemofiltration and hemodiafiltration for critically ill patients with acute kidney injury, fluid overload, or uremic syndrome.
• Prevention and Correction of Hypophosphatemia: Formulated specifically to prevent or treat CRRT-induced hypophosphatemia in patients requiring extended continuous dialysis support.
• Electrolyte and Acid-Base Normalization: Corrects metabolic acidosis and maintains physiological blood concentrations of sodium, potassium, calcium, magnesium, and chloride during continuous renal support.

Before Taking Phoxillum Solution: Contraindications & Precautions

Because Phoxillum is infused directly into the extracorporeal blood circuit of critically ill patients at high continuous flow rates, rigorous patient evaluation is mandatory. The solution contains fixed concentrations of potassium, calcium, and phosphate; selecting an inappropriate formulation variant or administering fluid to a patient with specific electrolyte toxicities can trigger fatal cardiac dysrhythmias or metabolic crises. Critical care teams must carefully monitor blood chemistry before and during infusion.

Who Should Not Receive Phoxillum Solution?

• Patients with severe hyperkalemia or hypercalcemia prior to starting therapy, unless explicitly managed under specialized nephrology protocols.
• Individuals with severe hyperphosphatemia (excessively high blood phosphate levels), as the phosphate component will exacerbate systemic toxicity.
• Patients with severe metabolic alkalosis, as the sodium bicarbonate buffer will further raise blood pH.
• Patients with known hypersensitivity to any of the active chemical ingredients in the formulation.

Phoxillum Solution, Pregnancy & Fertility

Animal reproduction studies have not been conducted with Phoxillum. Clinical experience confirms that maintaining stable fluid balance, electrolyte levels, and acid-base status during acute renal failure is critical for maternal and fetal survival. When indicated for acute kidney injury during pregnancy, Phoxillum should be administered under continuous intensive care and fetal monitoring. The physiological components match natural body electrolytes, and when dosed correctly, Phoxillum is not expected to adversely affect fertility or breastfed infants.

Tell Your Doctor Before Receiving Phoxillum Solution

Because Phoxillum is administered to patients in intensive care units, direct patient consultation is rarely possible. Healthcare surrogates or conscious patients must inform the critical care team of any history of severe heart failure, chronic liver disease, pre-existing parathyroid disorders, or baseline electrolyte abnormalities. Disclosing all concurrent medications especially digoxin, diuretics, vitamin D derivatives, or phosphate binders is essential, as these drugs interact directly with circulating electrolyte levels during continuous dialysis.

Phoxillum Solution Dosage & Administration

The dosage volume, flow rate, and choice of Phoxillum formulation variant (such as B22K 4/0 or BK 4/2.5) are prescribed by an intensive care physician or nephrologist based on the patient’s body weight, fluid balance targets, acid-base status, and current blood electrolyte concentrations.

Standard Phoxillum Solution Dosing

• CRRT Flow Rates: The total daily volume of Phoxillum replacement fluid or dialysate typically ranges from 1 to 4 liters per hour, tailored to achieve prescribed metabolic clearance targets.
• Formulation Selection: Formulations vary in potassium (e.g., 2 mEq/L or 4 mEq/L) and calcium content to allow precise matching with patient serum levels and regional citrate anticoagulation protocols.

How Phoxillum Solution Is Administered

• Administered exclusively by trained intensive care nurses or nephrology specialists using dedicated CRRT machines equipped with precise volumetric pumps.
• Supplied as a two-compartment bag. The red frangible pin or inter-compartmental seal between small Chamber A and large Chamber B must be broken and thoroughly mixed immediately prior to connecting to the CRRT circuit.
• Critical Safety Warning: The solution must never be infused unless both compartments are completely mixed. Infusing unmixed fluid can cause severe metabolic acidosis or severe electrolyte toxicity.

Phoxillum Solution Clinical Efficacy & Research

Clinical trials and critical care research support the use of phosphate-containing balanced solutions in continuous renal replacement therapy. Studies comparing traditional phosphate-free CRRT fluids with phosphate-containing solutions like Phoxillum demonstrate a dramatic reduction in the incidence of CRRT-induced hypophosphatemia (dropping from over 60 percent down to minimal levels).

Phoxillum Solution Side Effects & Safety Profile

While Phoxillum is designed to mirror normal plasma ultrafiltrate, continuous high-volume infusion carries clinical risks. Adverse events primarily result from improper formulation selection, unmixed bag infusion, or rapid fluid and electrolyte shifts during continuous therapy. Intensive care staff monitor vital signs and systemic blood parameters continuously to ensure safety.

Common Side Effects (>10%)

• Blood pressure fluctuations (hypotension or hypertension) related to continuous fluid volume removal or replacement during CRRT.
• Minor electrolyte shifts, including transient fluctuations in serum sodium, potassium, or calcium levels.
• Hypothermia caused by high-volume fluid movement through the extracorporeal circuit if blood warmers are not properly utilized.

Serious Phoxillum Solution Adverse Events

• Severe electrolyte disturbances, such as hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, or hyperphosphatemia, which can trigger dangerous heart rhythms or cardiac arrest.
• Severe acid-base disorders, including metabolic alkalosis from excess bicarbonate or uncorrected metabolic acidosis.
• Fluid overload leading to acute pulmonary edema, or severe hypovolemia resulting in circulatory collapse.

Managing Phoxillum Solution Side Effects

If blood electrolyte levels shift outside safe target ranges, the attending physician adjusts the CRRT flow rate or switches to a different Phoxillum formulation. Hypothermia is prevented by integrating inline fluid warmers into the dialysis circuit. If acute hemodynamic instability or cardiac dysrhythmias occur, the CRRT flow rate is paused, blood pressure support is optimized, and continuous cardiac resuscitation protocols are initiated as necessary.

Phoxillum Solution Drug Interactions & What to Avoid

Interactions with Phoxillum primarily involve the active clearance or accumulation of co-administered drugs during continuous renal replacement therapy. CRRT continuously filters water-soluble medications from the bloodstream while altering systemic electrolyte levels.

Phoxillum Solution Drug-Drug Interactions

• Digoxin: Electrolyte shifts (especially hypokalemia or hypomagnesemia) caused by continuous dialysis markedly increase the risk of fatal digoxin-induced cardiac toxicity. Serum potassium and magnesium levels must be audited frequently.
• Vitamin D Derivatives and Phosphate Binders: Co-administration with calcium- or phosphate-containing Phoxillum solutions can alter serum calcium and phosphate balance, requiring dosage adjustments.
• Dialyzable Drugs (e.g., antibiotics, antiarrhythmics): CRRT significantly increases the clearance of many critical care medications. Dosing adjustments and therapeutic drug monitoring are required to maintain effective blood levels.

Phoxillum Solution, Food & Alcohol

Because Phoxillum is administered to critically ill patients in intensive care environments requiring continuous kidney support, oral food and alcohol intake are managed per ICU critical care protocols. Patients usually receive specialized enteral or parenteral nutrition. Alcohol consumption is strictly contraindicated during critical illness and acute renal injury.

Phoxillum Solution: Missed Dose, Overdose & Storage

Phoxillum is delivered as a continuous automated infusion by medical personnel using advanced CRRT equipment. Patient-managed dosing schedules do not apply.

Missed Dose of Phoxillum Solution

Not applicable. Phoxillum is infused continuously according to a prescribed hourly rate. If therapy is temporarily interrupted due to circuit clotting, a new circuit is primed and treatment is resumed immediately.

Phoxillum Solution Overdose & Emergency

Overdose manifests as severe fluid overload, metabolic alkalosis, or electrolyte toxicities caused by excessive infusion rates or incorrect formulation selection. Symptoms include shortness of breath, pulmonary congestion, rapid heart rate, muscle weakness, or cardiac dysrhythmias. Treatment involves adjusting or pausing the CRRT infusion, modifying fluid removal rates (ultrafiltration), and providing targeted corrective electrolyte therapy under direct critical care supervision.

How to Store Phoxillum Solution

Store Phoxillum dual-compartment bags at controlled room temperature between 20 degrees Celsius and 25 degrees Celsius (68 degrees Fahrenheit to 77 degrees Fahrenheit). Do not freeze. Keep bags inside their protective overwrap until ready for use. Once the seal between compartments is broken and mixed, the solution should be used within 24 hours. Inspect the mixed fluid visually; it must be clear, colorless, and free of particulate matter or precipitation.

Phoxillum Solution Patient Management & Monitoring

Safe administration of Phoxillum during CRRT requires rigorous, continuous clinical monitoring. Intensive care teams track blood gases, serum electrolytes, and hemodynamic parameters to optimize treatment outcomes.

Tests Before Starting Phoxillum Solution

• Comprehensive metabolic panel (serum sodium, potassium, calcium, magnesium, chloride, phosphorus, BUN, and creatinine).
• Arterial blood gas (ABG) analysis to determine baseline blood pH, bicarbonate, and overall acid-base status.
• Complete blood count (CBC) and coagulation profile (PT/INR, PTT) prior to CRRT circuit initiation.

Monitoring During Phoxillum Solution Treatment

• Frequent serum electrolyte and blood gas measurements (every 4 to 12 hours) to guide flow rates and formulation choices.
• Continuous cardiac telemetry and hemodynamic monitoring (blood pressure, heart rate, oxygen saturation).
• Hourly fluid balance calculations to prevent hypovolemia or fluid overload.

Phoxillum Solution Do’s and Don’ts

• DO verify that the seal between small Chamber A and large Chamber B is broken and thoroughly mixed before connecting to the CRRT circuit.
• DO measure serum potassium and phosphate regularly to choose the appropriate Phoxillum formulation variant.
• DON’T infuse unmixed fluid from a single compartment under any circumstances.
• DON’T add unapproved medications directly into the Phoxillum bag due to the risk of chemical precipitation.

Frequently Asked Questions

References

• U.S. FDA Label Information for Phoxillum Solutions (Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, Sodium Phosphate Injection).
• U.S. FDA Drugs@FDA – Application Number: 207026, Initial Approval Date: January 2015.

Legal Disclaimer

This educational document is intended for informational purposes only and does not substitute for formal medical advice, clinical diagnosis, or specialized treatment. Always consult a qualified nephrologist, critical care physician, or healthcare provider with specific questions regarding continuous renal replacement therapy, electrolyte management, or prescription drug administration.